[25-NSE] IGM Biosciences, Inc. SEC Filing
IGM Biosciences, Inc. filed a Form 25 notifying the removal of its common stock from listing and/or registration on the Nasdaq Stock Market LLC. The filing includes statements that Nasdaq has complied with 17 CFR 240.12d2-2(b) and that the issuer has complied with 17 CFR 240.12d2-2(c) governing voluntary withdrawal. The document is signed by Tara Petta, AVP and dated 2025-08-14. The filing does not disclose an effective date for removal, the specific rule provision selected on the form, or the underlying reasons for the removal.
IGM Biosciences, Inc. ha depositato un Modulo 25 notificando la rimozione delle sue azioni ordinarie dalla quotazione e/o registrazione presso il Nasdaq Stock Market LLC. Nel deposito si dichiara che Nasdaq ha adempiuto a 17 CFR 240.12d2-2(b) e che l'emittente ha rispettato 17 CFR 240.12d2-2(c) relativi al ritiro volontario. Il documento è firmato da Tara Petta, AVP e datato 2025-08-14. Il deposito non indica la data di efficacia della rimozione, la specifica disposizione normativa selezionata nel modulo né le ragioni sottostanti alla rimozione.
IGM Biosciences, Inc. presentó un Formulario 25 notificando la retirada de sus acciones comunes de la cotización y/o registro en el Nasdaq Stock Market LLC. La presentación incluye declaraciones de que Nasdaq cumplió con 17 CFR 240.12d2-2(b) y que el emisor cumplió con 17 CFR 240.12d2-2(c) relativas a la retirada voluntaria. El documento está firmado por Tara Petta, AVP y fechado el 2025-08-14. La presentación no revela la fecha efectiva de la retirada, la disposición normativa específica seleccionada en el formulario ni las razones subyacentes de la retirada.
IGM Biosciences, Inc.는 Form 25를 제출하여 자사의 보통주를 Nasdaq Stock Market LLC의 상장 및/또는 등록에서 삭제할 것임을 통지했습니다. 제출 문서에는 Nasdaq가 17 CFR 240.12d2-2(b)를 준수했으며 발행인은 자발적 철회를 규정한 17 CFR 240.12d2-2(c)를 준수했다는 내용이 포함되어 있습니다. 문서는 Tara Petta, AVP의 서명과 2025-08-14의 일자를 담고 있습니다. 제출서에는 삭제의 효력 발생일, 양식에서 선택한 구체적 규정 조항, 또는 삭제의 근본적인 사유는 기재되어 있지 않습니다.
IGM Biosciences, Inc. a déposé un Formulaire 25 notifiant le retrait de ses actions ordinaires de la cotation et/ou de l'enregistrement sur le Nasdaq Stock Market LLC. Le dépôt indique que le Nasdaq a respecté le 17 CFR 240.12d2-2(b) et que l'émetteur a respecté le 17 CFR 240.12d2-2(c) régissant le retrait volontaire. Le document est signé par Tara Petta, AVP et daté du 2025-08-14. Le dépôt ne précise ni la date d'entrée en vigueur du retrait, ni la disposition réglementaire spécifique choisie sur le formulaire, ni les raisons sous-jacentes du retrait.
IGM Biosciences, Inc. hat ein Form 25 eingereicht, mit dem die Streichung ihrer Stammaktien von der Notierung und/oder Registrierung an der Nasdaq Stock Market LLC angezeigt wird. Die Einreichung enthält Angaben, dass die Nasdaq 17 CFR 240.12d2-2(b) eingehalten hat und der Emittent 17 CFR 240.12d2-2(c) betreffend den freiwilligen Rückzug erfüllt hat. Das Dokument ist von Tara Petta, AVP unterschrieben und datiert auf den 2025-08-14. In der Einreichung werden weder ein Wirksamkeitsdatum für die Streichung, noch die konkret auf dem Formular gewählte Regelbestimmung, noch die zugrundeliegenden Gründe für die Streichung genannt.
- None.
- None.
Insights
TL;DR: Nasdaq filed to remove IGMS common stock; filing shows procedural compliance but provides no timing or rationale.
The Form 25 formally notifies market participants that IGM Biosciences' common stock is to be removed from Nasdaq listing and/or registration. The document explicitly cites compliance with 17 CFR 240.12d2-2(b) by the Exchange and 17 CFR 240.12d2-2(c) by the issuer, and it is signed and dated 2025-08-14 by an AVP of Nasdaq. Material investor information typically tied to such a filing—an effective removal date, reason for delisting or withdrawal, and any transition arrangements for trading—is absent from the filing. The lack of those details increases uncertainty for holders about timing and trading implications.
TL;DR: Form 25 signals a removal/withdrawal event with exchange and issuer compliance statements; the filing omits explanatory details or next steps.
The submission meets procedural requirements by including compliance statements under 17 CFR 240.12d2-2(b) and 240.12d2-2(c) and is executed by Nasdaq personnel. From a governance and disclosure standpoint, the filing is limited to the notification itself and does not contain the issuer's explanation, board actions, shareholder communications, or effective-date information. For stakeholders, this means the document confirms an imminent change in listing status but does not provide governance context or operational details that would clarify implications for shareholders.
IGM Biosciences, Inc. ha depositato un Modulo 25 notificando la rimozione delle sue azioni ordinarie dalla quotazione e/o registrazione presso il Nasdaq Stock Market LLC. Nel deposito si dichiara che Nasdaq ha adempiuto a 17 CFR 240.12d2-2(b) e che l'emittente ha rispettato 17 CFR 240.12d2-2(c) relativi al ritiro volontario. Il documento è firmato da Tara Petta, AVP e datato 2025-08-14. Il deposito non indica la data di efficacia della rimozione, la specifica disposizione normativa selezionata nel modulo né le ragioni sottostanti alla rimozione.
IGM Biosciences, Inc. presentó un Formulario 25 notificando la retirada de sus acciones comunes de la cotización y/o registro en el Nasdaq Stock Market LLC. La presentación incluye declaraciones de que Nasdaq cumplió con 17 CFR 240.12d2-2(b) y que el emisor cumplió con 17 CFR 240.12d2-2(c) relativas a la retirada voluntaria. El documento está firmado por Tara Petta, AVP y fechado el 2025-08-14. La presentación no revela la fecha efectiva de la retirada, la disposición normativa específica seleccionada en el formulario ni las razones subyacentes de la retirada.
IGM Biosciences, Inc.는 Form 25를 제출하여 자사의 보통주를 Nasdaq Stock Market LLC의 상장 및/또는 등록에서 삭제할 것임을 통지했습니다. 제출 문서에는 Nasdaq가 17 CFR 240.12d2-2(b)를 준수했으며 발행인은 자발적 철회를 규정한 17 CFR 240.12d2-2(c)를 준수했다는 내용이 포함되어 있습니다. 문서는 Tara Petta, AVP의 서명과 2025-08-14의 일자를 담고 있습니다. 제출서에는 삭제의 효력 발생일, 양식에서 선택한 구체적 규정 조항, 또는 삭제의 근본적인 사유는 기재되어 있지 않습니다.
IGM Biosciences, Inc. a déposé un Formulaire 25 notifiant le retrait de ses actions ordinaires de la cotation et/ou de l'enregistrement sur le Nasdaq Stock Market LLC. Le dépôt indique que le Nasdaq a respecté le 17 CFR 240.12d2-2(b) et que l'émetteur a respecté le 17 CFR 240.12d2-2(c) régissant le retrait volontaire. Le document est signé par Tara Petta, AVP et daté du 2025-08-14. Le dépôt ne précise ni la date d'entrée en vigueur du retrait, ni la disposition réglementaire spécifique choisie sur le formulaire, ni les raisons sous-jacentes du retrait.
IGM Biosciences, Inc. hat ein Form 25 eingereicht, mit dem die Streichung ihrer Stammaktien von der Notierung und/oder Registrierung an der Nasdaq Stock Market LLC angezeigt wird. Die Einreichung enthält Angaben, dass die Nasdaq 17 CFR 240.12d2-2(b) eingehalten hat und der Emittent 17 CFR 240.12d2-2(c) betreffend den freiwilligen Rückzug erfüllt hat. Das Dokument ist von Tara Petta, AVP unterschrieben und datiert auf den 2025-08-14. In der Einreichung werden weder ein Wirksamkeitsdatum für die Streichung, noch die konkret auf dem Formular gewählte Regelbestimmung, noch die zugrundeliegenden Gründe für die Streichung genannt.
FAQ
What action did Nasdaq take regarding IGM Biosciences (IGMS)?
When was the Form 25 for IGMS signed and by whom?
Which class of securities is affected for IGM Biosciences (IGMS)?
Does the filing state whether the withdrawal is voluntary or initiated by the exchange?
Does the Form 25 disclose the effective date or reasons for removal?
